Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
06 October 2022 - 6:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: October 2022
Commission file number: 001-36578
ENLIVEX THERAPEUTICS LTD.
(Translation of registrant’s name into English)
14 Einstein Street, Nes Ziona, Israel 7403618
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
Annual General Meeting of
Shareholders
On
October 5, 2022, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the
“Company”), announced that it will hold its 2022 Annual General Meeting of
Shareholders of the Company (the “Annual Meeting”) on Thursday, November 17, 2022,
beginning at 7:00 p.m. Israel time, at the offices of the Company located at 14
Einstein Street, Nes Ziona, Israel 7403618. Copies of the proxy statement, the related proxy
card and the related notice of internet availability of proxy materials for beneficial owners of the Company’s ordinary shares
trading on the Nasdaq Capital Market are attached to this Report on Form 6-K as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3,
respectively, and incorporated herein by reference, and the information set forth under the heading “Board Practices,
Corporate Governance and Compensation of Executive Officers and Directors” in Exhibit 99.1 is incorporated by reference into
the Company’s registration statements on Forms S-8, F-3 and F-3MEF (File No. 333-256799,
File No. 333-232413,
File No. 333-232009,
File No. 333-252926
and File No. 333-264561),
filed with the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Enlivex Therapeutics Ltd. |
|
(Registrant) |
|
|
|
By: |
/s/ Oren Hershkovitz |
|
Name:
Title: |
Oren Hershkovitz
Chief Executive Officer |
Date: October 5, 2022
2
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Apr 2023 to Apr 2024